{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:12:38Z","timestamp":1784113958828,"version":"3.55.0"},"publisher-location":"Cham","reference-count":52,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031871665","type":"print"},{"value":"9783031871672","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/82_2024_267","type":"book-chapter","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T14:04:46Z","timestamp":1716300286000},"page":"41-52","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Logic and History of Passive Immunity and Antibody Therapies"],"prefix":"10.1007","author":[{"given":"Arturo","family":"Casadevall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Paneth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"issue":"2","key":"267_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1084\/jem.79.2.137","volume":"79","author":"OT Avery","year":"1944","unstructured":"Avery OT, Macleod CM, McCarty M (1944) Studies on the chemical nature of the substance inducing transformation of pneumococcal types: Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type IIII. J Exp Med 79(2):137\u2013158","journal-title":"J Exp Med"},{"issue":"5","key":"267_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.2165\/00019053-199202050-00008","volume":"2","author":"SL Barriere","year":"1992","unstructured":"Barriere SL (1992) The economic impact of HA-1A (Centoxin) against endotoxin. Pharmacoeconomics 2(5):408\u2013413","journal-title":"Pharmacoeconomics"},{"key":"267_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jama.1976.03260270028022","volume":"235","author":"PA Blake","year":"1976","unstructured":"Blake PA, Feldman RA, Buchanan TM, Brooks GF, Bennett JV (1976) Serologic therapy of tetanus in the United States. JAMA 235:42\u201344","journal-title":"JAMA"},{"key":"267_CR4","unstructured":"Borrell B (2008) What is truth serum? Scientific American"},{"key":"267_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1084\/jem.56.4.507","volume":"55","author":"M Brodie","year":"1932","unstructured":"Brodie M (1932) A comparison between convalescent serum and non-convalescent serum in poliomyelitis. J Exp Med 55:507\u2013519","journal-title":"J Exp Med"},{"key":"267_CR6","doi-asserted-by":"crossref","unstructured":"Carpenter CM, Boak RA (1936) The treatment of human brucellosis. A review of current therapeutic methods. Medicine 15:103\u2013125","DOI":"10.1097\/00005792-193602000-00002"},{"issue":"7","key":"267_CR7","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/cid\/cix067","volume":"64","author":"A Casadevall","year":"2017","unstructured":"Casadevall A (2017) Crisis in infectious diseases: 2 decades later. Clin Infect Dis off Publ Infect Dis Soc Am 64(7):823\u2013828","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"issue":"3","key":"267_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/mmi.14421","volume":"113","author":"A Casadevall","year":"2020","unstructured":"Casadevall A, Fang FC (2020) The intracellular pathogen concept. Mol Microbiol 113(3):541\u2013545","journal-title":"Mol Microbiol"},{"key":"267_CR9","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1128\/AAC.38.8.1695","volume":"38","author":"A Casadevall","year":"1994","unstructured":"Casadevall A, Scharff MD (1994) Serum Therapy\u201d revisited: animal models of infection and the development of passive antibody therapy. Antimicrob Agents Chemotherap 38:1695\u20131702","journal-title":"Antimicrob Agents Chemotherap"},{"key":"267_CR10","doi-asserted-by":"crossref","unstructured":"Casadevall A, Dragotakes Q, Johnson PW, Senefeld JW, Klassen SA, Wright RS et al (2021a) Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. Elife 10","DOI":"10.7554\/eLife.69866"},{"key":"267_CR11","doi-asserted-by":"crossref","unstructured":"Casadevall A, Pirofski LA, Joyner MJ (2021b) The Principles of antibody therapy for infectious diseases with relevance for COVID-19. mBio 12(2)","DOI":"10.1128\/mBio.03372-20"},{"key":"267_CR12","doi-asserted-by":"crossref","unstructured":"Casadevall A, Joyner MJ, Pirofski LA, Senefeld JW, Shoham S, Sullivan D et al (2023) Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy. Exp Rev Respir Med 1\u201315","DOI":"10.1080\/17476348.2023.2208349"},{"key":"267_CR13","first-page":"589","volume":"108","author":"RL Cecil","year":"1937","unstructured":"Cecil RL (1937) Effects of very early serum treatment in pneumococcus Type I pneumonia. JAMA 108:589\u2013692","journal-title":"JAMA"},{"key":"267_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1021\/ja01207a034","volume":"68","author":"EJ Cohn","year":"1946","unstructured":"Cohn EJ, Strong LE et al (1946) Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 68:459\u2013475","journal-title":"J Am Chem Soc"},{"issue":"8","key":"267_CR15","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.4049\/jimmunol.163.8.4087","volume":"163","author":"BT Edelson","year":"1999","unstructured":"Edelson BT, Cossart P, Unanue ER (1999) Cutting edge: paradigm revisited: antibody provides resistance to Listeria infection. J Immunol 163(8):4087\u20134090","journal-title":"J Immunol"},{"key":"267_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/infdis\/43.6.531","volume":"43","author":"LD Felton","year":"1928","unstructured":"Felton LD (1928) The units of protective antibody in anti-pneumococcus serum and antibody solution. J Infect Dis 43:531\u2013542","journal-title":"J Infect Dis"},{"key":"267_CR17","volume":"71","author":"D Focosi","year":"2023","unstructured":"Focosi D, McConnell S, Sullivan DJ, Casadevall A (2023) Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment. Drug Resist Updates Rev Commentaries Antimicrob Anticancer Chemother 71:100991","journal-title":"Drug Resist Updates Rev Commentaries Antimicrob Anticancer Chemother"},{"key":"267_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-194002000-00001","volume":"19","author":"L Foshay","year":"1940","unstructured":"Foshay L (1940) Tularemia: a summary of certain aspects of the disease including methods for early diagnosis and the results of serum treatment in 600 patients. Medicine 19:1\u201381","journal-title":"Medicine"},{"key":"267_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1056\/NEJM193704082161401","volume":"216","author":"LRD Fothergill","year":"1937","unstructured":"Fothergill LRD (1937) Hemophilus influenzae (Pfeiffer bacillus) meningitis and its specific treatment. N Engl J Med 216:587\u2013590","journal-title":"N Engl J Med"},{"key":"267_CR20","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0022-3476(42)80006-2","volume":"20","author":"WP Frank","year":"1942","unstructured":"Frank WP, Patton EF, Hamilton PM (1942) Treatment of whooping cough bronchopneumonia. J Pediatr 20:720\u2013722","journal-title":"J Pediatr"},{"key":"267_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2105\/AJPH.25.5.595","volume":"25","author":"JR Gallagher","year":"1935","unstructured":"Gallagher JR (1935) Use of convalescent measles serum to control measles in a preparatory school. Am J Public Health 25:595\u2013598","journal-title":"Am J Public Health"},{"key":"267_CR22","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1128\/CMR.11.3.514","volume":"11","author":"A Glatman-Freedman","year":"1998","unstructured":"Glatman-Freedman A, Casadevall A (1998) Serum therapy for tuberculosis revisited: a reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 11:514\u2013532","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"267_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1017\/S0022172400031879","volume":"27","author":"F Griffith","year":"1928","unstructured":"Griffith F (1928) The significance of pneumococcal types. J Hyg 27(2):113\u2013159","journal-title":"J Hyg"},{"issue":"Suppl","key":"267_CR24","doi-asserted-by":"publisher","first-page":"A266","DOI":"10.1093\/infdis\/133.Supplement_2.A266","volume":"133","author":"MA Hattwick","year":"1976","unstructured":"Hattwick MA, Corey L, Creech WB (1976) Clinical use of human globulin immune to rabies virus. J Infect Dis 133(Suppl):A266\u2013A272","journal-title":"J Infect Dis"},{"issue":"3016","key":"267_CR25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/bmj.2.3016.425","volume":"2","author":"F Ivens","year":"1918","unstructured":"Ivens F (1918) The preventive and curative treatment of gas gangrene by mixed serums. BMJ 2(3016):425","journal-title":"BMJ"},{"key":"267_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G Kohler","year":"1975","unstructured":"Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495\u2013497","journal-title":"Nature"},{"key":"267_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0001-706X(98)00038-2","volume":"70","author":"J Lang","year":"1998","unstructured":"Lang J, Attanath P, Quiambao B, Singhasivanon V, Chanthavanich P, Montalban C et al (1998) Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered alone or in combination with a purified, Vero-cell rabies vaccine. Acta Trop 70:317\u2013333","journal-title":"Acta Trop"},{"key":"267_CR28","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1001\/jama.1941.02820140018005","volume":"14","author":"PF Lucchesi","year":"1941","unstructured":"Lucchesi PF, Gildersleeve N (1941) The treatment of anthrax. JAMA 14:1506\u20131508","journal-title":"JAMA"},{"issue":"8","key":"267_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","volume":"145","author":"TC Luke","year":"2006","unstructured":"Luke TC, Kilbane EM, Jackson JL, Hoffman SL (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 145(8):599\u2013609","journal-title":"Ann Intern Med"},{"issue":"1","key":"267_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiu396","volume":"211","author":"J Mair-Jenkins","year":"2015","unstructured":"Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS et al (2015) The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 211(1):80\u201390","journal-title":"J Infect Dis"},{"key":"267_CR31","doi-asserted-by":"crossref","unstructured":"Maiztegui JI, Fernandez NJ, de Damilano AJ (1979) Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2(98154):1216\u20131217","DOI":"10.1016\/S0140-6736(79)92335-3"},{"key":"267_CR32","unstructured":"Manson-Bahr P (1939) The dysenteric disorders. The diagnosis and treatment of dysentery, sprue, colitis, and other diarrheas in general practice. Baltimore: The Williams & Wilkins Co."},{"issue":"8","key":"267_CR33","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1172\/JCI19361","volume":"112","author":"JD Nosanchuk","year":"2003","unstructured":"Nosanchuk JD, Steenbergen JN, Shi L, Deepe GS Jr, Casadevall A (2003) Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest 112(8):1164\u20131175","journal-title":"J Clin Invest"},{"key":"267_CR34","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/jama.1932.02740650008003","volume":"99","author":"WH Park","year":"1932","unstructured":"Park WH (1932) Therapeutic use of antipoliomyelitits serum in preparalytic cases of poliomyelitis. JAMA 99:1050\u20131053","journal-title":"JAMA"},{"key":"267_CR35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1001\/jama.1926.02680080022009","volume":"87","author":"WH Park","year":"1926","unstructured":"Park WH, Freeman RG (1926) The prophylactic use of measles convalescent serum. JAMA 87:556\u2013561","journal-title":"JAMA"},{"key":"267_CR36","doi-asserted-by":"crossref","unstructured":"Pati I, Cruciani M, Candura F, Massari MS, Piccinini V, Masiello F et al (2023) Hyperimmune globulins for the management of infectious diseases. Viruses 15(7)","DOI":"10.3390\/v15071543"},{"issue":"21","key":"267_CR37","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1001\/jama.1941.02820210012002","volume":"116","author":"N Plummer","year":"1941","unstructured":"Plummer N, Liebmann J, Solomon S, Kammerer W, Kalkstein M, Ensworth HK (1941) Chemotherapy versus combined chemotherapy and serum in the treatment of pneumonia: a study of 607 alternated cases. J Am Med Assoc 116(21):2366\u20132371","journal-title":"J Am Med Assoc"},{"issue":"1","key":"267_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/archpedi.1946.02020240008001","volume":"71","author":"AC Rambar","year":"1946","unstructured":"Rambar AC (1946) Mumps: use of convalescent serum in the treatment and prophylaxis of orchitis. Am J Dis Child 71(1):1\u201313","journal-title":"Am J Dis Child"},{"key":"267_CR39","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1001\/jama.1933.02740200018004","volume":"100","author":"AB Sabin","year":"1933","unstructured":"Sabin AB (1933) Immediate pneumococcus typing directly from sputum by the Neufeld reaction. JAMA 100:1584\u20131586","journal-title":"JAMA"},{"issue":"3","key":"267_CR40","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jinf.2016.11.009","volume":"74","author":"F Sahr","year":"2017","unstructured":"Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM et al (2017) Evaluation of convalescent whole blood for treating Ebola virus disease in Freetown, Sierra Leone. J Infect 74(3):302\u2013309","journal-title":"J Infect"},{"issue":"12","key":"267_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003872","volume":"18","author":"JW Senefeld","year":"2021","unstructured":"Senefeld JW, Johnson PW, Kunze KL, Bloch EM, van Helmond N, Golafshar MA et al (2021) Access to and safety of COVID-19 convalescent plasma in the United States expanded access program: a national registry study. PLoS Med 18(12):e1003872","journal-title":"PLoS Med"},{"issue":"5","key":"267_CR42","first-page":"499","volume":"7","author":"JW Senefeld","year":"2023","unstructured":"Senefeld JW, Gorman EK, Johnson PW, Moir ME, Klassen SA, Carter RE et al (2023) Rates among hospitalized patients with COVID-19 treated with convalescent plasma: a systematic review and meta-analysis. Mayo Clinic Proc: Innov Qual Outcomes 7(5):499\u2013513","journal-title":"Mayo Clinic Proc: Innov Qual Outcomes"},{"key":"267_CR43","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/0002-9343(84)90988-4","volume":"76","author":"CO Tacket","year":"1984","unstructured":"Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA (1984) Equine antitoxin use and other factors that predict outcome in Type A foodborne botulism. Am J Med 76:794\u2013798","journal-title":"Am J Med"},{"key":"267_CR44","doi-asserted-by":"publisher","first-page":"15688","DOI":"10.1073\/pnas.95.26.15688","volume":"95","author":"R Teitelbaum","year":"1998","unstructured":"Teitelbaum R, Glatman-Freedman A, Chen B, Robbins JB, Unanue ER, Casadevall A et al (1998) A monoclonal antibody recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci 95:15688\u201315693","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"267_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1511812","volume":"374","author":"J van Griensven","year":"2016","unstructured":"van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S et al (2016) Evaluation of convalescent plasma for Ebola virus disease in guinea. N Engl J Med 374(1):33\u201342","journal-title":"N Engl J Med"},{"key":"267_CR46","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2105\/AJPH.19.12.1287","volume":"19","author":"AB Wadsworth","year":"1929","unstructured":"Wadsworth AB (1929) The hemolytic streptococci and antistreptococcus serum in scarlet fever. Am J Public Health 19:1287\u20131302","journal-title":"Am J Public Health"},{"key":"267_CR47","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/clinids\/17.5.913","volume":"17","author":"DA Watson","year":"1993","unstructured":"Watson DA, Musher DM, Jacobson JW, Verhoef J (1993) A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. Clin Infect Dis 17:913\u2013924","journal-title":"Clin Infect Dis"},{"key":"267_CR48","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S0022-3476(33)80113-2","volume":"3","author":"C Wesselhoeft","year":"1933","unstructured":"Wesselhoeft C (1933) The present status of serum treatment for acute poliomyelitis. J Pediatr 3:330\u2013351","journal-title":"J Pediatr"},{"key":"267_CR49","first-page":"1389","volume":"19","author":"C Wesselhoeft","year":"1994","unstructured":"Wesselhoeft C (1994) Treatment of scarlet fever and diphtheria. Med Clin N Am 19:1389\u20131429","journal-title":"Med Clin N Am"},{"key":"267_CR50","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/medhum-2011-010157","volume":"38","author":"PC Wever","year":"2012","unstructured":"Wever PC, van Bergen L (2012) Prevention of tetanus during the First World War. Med Humanit 38:78\u201382","journal-title":"Med Humanit"},{"issue":"6","key":"267_CR51","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/infdis\/166.6.1367","volume":"166","author":"CH Wortel","year":"1992","unstructured":"Wortel CH, von der M\u00f6hlen MA, van Deventer SJ, Sprung CL, Jastremski M, Lubbers MJ et al (1992) Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis 166(6):1367\u20131374","journal-title":"J Infect Dis"},{"key":"267_CR52","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJM199102143240701","volume":"324","author":"EJ Ziegler","year":"1991","unstructured":"Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE et al (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 324:429\u2013436","journal-title":"N Engl J Med"}],"container-title":["Current Topics in Microbiology and Immunology","Convalescent Plasma and Other Antibody Therapies for Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2024_267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:01:26Z","timestamp":1784113286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2024_267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031871665","9783031871672"],"references-count":52,"URL":"https:\/\/doi.org\/10.1007\/82_2024_267","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"22 May 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"Neither author has any conflicts to declare nor received any funding for this work.","order":1,"name":"Ethics","label":"Declarations","group":{"name":"EthicsHeading","label":"Ethics"}}]}}